Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2025 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals receives INN isupartob sodium recognizing first-in-class drug status for M6229

Matisse Pharmaceuticals receives INN (International Non-proprietary Name) isupartob sodium from the WHO recognizing first-in-class drug status for M6229.
November 13, 2025 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers

Successful phase 1 with prolonged infusion duration could offer an effective solution for irreversibly stopping harmful inflammatory responses in sepsis.